A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products.
Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
The Company proposes to spin-off and separately list the shares of Dermavon, a subsidiary of the Company, on the Main Board of the Stock Exchange. The Proposed Spin-off, if proceeded, is expected to be implemented through a distribution in specie by the Company of all the shares in Dermavon that it holds to the Shareholders in proportion to their respective shareholding in the Company as of a record date to be determined by the Board for the purpose of ascertaining the Shareholders’ entitlements. The separate listing of the shares of Dermavon on the Stock Exchange constitutes a spin-off of Dermavon by the Company under the Practice Note 15 to the Listing Rules. The Stock Exchange has confirmed that the Company may proceed with the Proposed Spin-off. In connection with the Proposed Spin-off, on 22 April 2025, Dermavon submitted an application to the Stock Exchange for the listing of, and permission […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.